Reduction in sales of bovine spongiform encephalopathy (BSE) testing kits
First written in FY2017. 6 of 21 entries say "Worsened", first in FY2020-Q1. Latest entry: 2026-08-07.
Immuno-Biological Laboratories moved to the "Worse" side of this theme in 2019.
The whole theme swung hardest in 2017: 1 of 6 companies on the "Worse" side.
3 other companies' latest entry also says "Advanced".
- 2026-08-07AdvancedEarnings
「Owing to increased overseas sales of the flagship ELISA kits and higher sales of the bovine spongiform encephalopathy testing kit (BSE kit), an in vitro diagnostic product for veterinary use, among other factors」
The BSE kit, for which sales had been declining through the previous fiscal year, was cited as a contributor to revenue growth in the first quarter due to increased sales. - FY2026-H1WorsenedAnnual report
「Revenue from this service increased significantly year on year. Although sales of bovine spongiform encephalopathy measurement kits (BSE kits), which are in vitro diagnostic drugs for animals, declined, overseas sales of ELISA kits, one of our main products, and bulk sales of antibodies used as raw materials for in vitro diagnostic drugs contributed to the increase.」
BSE kit sales declined from the same period of the previous year. However, revenue from the diagnostic reagent services business increased, driven by overseas ELISA kit sales and bulk antibody sales. - FY2024BSE kit sales recognized but below forecastAnnual report
「Meanwhile, sales of other products were below forecast, despite the recognition of sales from large antibody orders and sales of bovine spongiform encephalopathy measurement kits (BSE kits), which are in vitro diagnostic drugs for animals.」
Sales of BSE kits and other products were recognized, but total sales of other products fell below forecast. Following the previous timing delays in revenue recognition, the focus has shifted to evaluating full-year results. - FY2024-Q3Timing of revenue recognition for BSE kits and other products deferred to the fourth quarter or laterAnnual report
「Revenue from antibody products and veterinary in vitro diagnostic BSE testing kits, which had been recorded in a concentrated manner during the corresponding accounting period of the previous year, is now expected to be recognized from the fourth-quarter consolidated accounting period of the current fiscal year onward.」
For BSE kits and other products whose sales were largely recognized in the same period of the previous year, recognition in the current period is now expected from the fourth quarter onward. - FY2024-Q2RestatedAnnual report
「Sales of the veterinary in vitro diagnostic BSE testing kit remained at approximately the same level as the previous year.」
For the BSE kit, amid continued declines and fluctuations in demand, sales during the cumulative period under review remained at approximately the previous year's level. - FY2023-Q2RestatedAnnual report
「Revenue from the business increased significantly year on year because sales of the veterinary in vitro diagnostic BSE testing kit were recorded in the diagnostic reagent services business, and the benefits of an information strategy using e-marketing, including social media, in overseas sales activities began to emerge, resulting in a substantial increase in overseas sales of the mainstay ELISA kits and antibodies.」
For the BSE kit, for which demand has continued to decline, sales were recorded during the cumulative period of the second quarter. Sales were recorded for the second consecutive quarter. - FY2023-Q1BSE kit sales recorded in the first quarterAnnual report
「Sales in this business benefited from the recording of sales of a veterinary in vitro diagnostic bovine spongiform encephalopathy measurement kit (BSE kit), as well as the initial results of an information strategy using e-marketing, including social media, in overseas sales activities. Sales of the core EIA measurement kits and antibodies overseas increased substantially from the previous year.」
For the BSE kit, for which demand has continued to decline, sales were recorded in the first quarter. The actual timing of recognition changed from the previously stated plan to record sales in the third quarter or later. - FY2022-Q2BSE kit sales deferred to the third quarter or laterAnnual report
「Although sales of diagnostic product raw materials to overseas companies were recorded in the diagnostic reagent services business, revenue from the business declined significantly year on year because sales of the veterinary in vitro diagnostic BSE testing kit were recorded in the third quarter or later.」
No BSE kit sales were recorded during the cumulative period of the second quarter, and sales were deferred to the third quarter or later, making this a factor behind the decline in revenue from the antibody-related business. - FY2022-Q1WorsenedAnnual report
「In the pharmaceutical-related business, sales declined year on year because, although diagnostic product raw materials were sold to overseas companies, there were no sales of the veterinary in vitro diagnostic BSE testing kit.」
For the BSE kit, for which declining demand has continued, there were no sales during the first quarter, making it a factor behind the decline in revenue from the pharmaceutical-related business. - FY2021AdvancedAnnual report
「In the pharmaceutical-related business, sales of the core veterinary in vitro diagnostic product, the BSE testing kit, progressed favorably and significantly exceeded the previous year's level.」
For the BSE kit, for which declining demand had been reported, sales progressed favorably during the fiscal year and significantly exceeded the previous year's level. - FY2021-Q1Revenue recorded despite declining demandAnnual report
「Meanwhile, in the pharmaceutical-related business, demand for the core veterinary in vitro diagnostic product, the BSE testing kit, has declined in recent years, but the company was able to record sales during the first quarter.」
Although demand for the BSE kit has continued to decline in recent years, sales were recorded in the first quarter. The company reported both the long-term trend of declining demand and sales recorded during the quarter. - FY2020WorsenedAnnual report
「Revenue from the pharmaceutical-related business declined significantly year on year due to lower demand for the core veterinary in vitro diagnostic product, the BSE testing kit, and lower sales of products supplied as raw materials to Europe, among other factors.」
Declining demand for the BSE kit continued, making it a factor behind the decline in pharmaceutical-related revenue together with lower sales of products supplied as raw materials to Europe. - FY2020-Q3WorsenedAnnual report
「Revenue from the pharmaceutical-related business declined significantly year on year due to lower demand for the core veterinary in vitro diagnostic product, the BSE testing kit, and lower sales of products supplied as raw materials to Europe, among other factors.」
Revenue from the pharmaceutical-related business declined significantly year on year due to lower demand for the BSE kit and lower sales of products supplied as raw materials to Europe. - FY2020-Q2WorsenedAnnual report
「Revenue from the pharmaceutical-related business declined significantly year on year due to lower demand for the core veterinary in vitro diagnostic product, the BSE testing kit, and lower sales of products supplied as raw materials to Europe.」
The BSE kit became a factor behind the decline in pharmaceutical-related revenue due to lower demand, together with lower sales of products supplied as raw materials to Europe. - FY2020-Q1WorsenedAnnual report
「In the pharmaceutical-related business, the impact of lower revenue due to declining demand for the core veterinary in vitro diagnostic product, the BSE testing kit, was significant.」
The company stated that declining demand for the BSE kit had a significant impact on revenue, and that the effects of unstable demand and declining sales continued. - FY2019Unstable demand and declining sales of BSE testing kitsAnnual report
「Demand has become unstable for BSE testing of all cattle following the Ministry of Health, Labour and Welfare's review of universal testing in 2013. As a result, sales declined from the previous fiscal year.」
The explanation changed from reporting an increase in sales through the third quarter to stating that, for the full fiscal year, demand became unstable following the review of universal BSE testing and sales of BSE testing kits declined year on year. - FY2019-Q3RestatedAnnual report
「In the pharmaceutical-related business, sales of the core veterinary in vitro diagnostic product, the BSE testing kit, increased significantly year on year.」
The company continued to explain that sales of the BSE testing kit, for which a declining trend had been indicated, increased significantly year on year. - FY2019-Q2Significant increase in BSE kit salesAnnual report
「In the pharmaceutical-related business, sales of the core veterinary in vitro diagnostic product, the BSE testing kit, increased significantly year on year.」
For the BSE testing kit, for which a declining trend in sales had been reported, sales increased significantly year on year during the cumulative period of the second quarter. - FY2019-Q1Renewed increase in BSE kit salesAnnual report
「In the pharmaceutical-related business, the company was able to record sales of its core veterinary in vitro diagnostic product, the BSE testing kit, although no sales had been recorded in the same period of the previous year.」
For the BSE kit, for which a declining trend had been reported, the company recorded sales during the quarter that had not been recorded in the same period of the previous year. - FY2018-Q3Increase in BSE testing kit salesAnnual report
「In the pharmaceutical-related business, sales of raw materials for mycoplasma infection diagnostic products declined due to the impact of changes in manufacturing methods and lot sizes, among other factors. Sales of raw materials for Alzheimer's disease in vitro diagnostic products sold overseas also declined year on year, partly because a substantial amount of revenue had been recorded at the end of the previous fiscal year. However, total sales increased year on year because revenue from the company's in-house manufactured veterinary in vitro diagnostic BSE testing kit increased.」
The company explained that sales of BSE testing kits, for which a declining trend had been reported, increased during the cumulative period under review. However, it did not state that the long-term shift in the sales structure had been completed. - FY2017First statedAnnual report
「As sales of Nippibull BSE kits, veterinary in vitro diagnostic products for bovine spongiform encephalopathy, continue to decline, the company will assess the potential of antibodies it has developed in-house not only as research-use reagents but also as diagnostic products and pharmaceuticals, and will begin developing diagnostic products in-house for candidates with high potential.」
The company described a business structure in which sales of BSE testing kits are declining due to factors including a reduction in the number of tests, and explained its policy of shifting toward the development of new diagnostic products.